UBS Group
CVAC

UBS Group’s CureVac CVAC Stock Holding History

UBS Group’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,144
Closed -$238K – 10400
2022
Q1 		$238K Hold
12,144
– – ﹤0.01% 5219
2021
Q4 		$417K Hold
12,144
– – ﹤0.01% 5121
2021
Q3 		$663K Hold
12,144
– – ﹤0.01% 4522
2021
Q2 		$892K Buy
+12,144
New +$1.21M ﹤0.01% 4272

UBS Group's CVAC Position: Q1 2026 in Review

UBS Group sold out of CureVac (CVAC) in Q1 2026, closing a stake of 64,879 shares — an estimated $293K sold.

UBS Group first reported a position in CVAC in Q3 2020 and held it in 22 quarters. The position peaked at $8.35M in Q2 2021. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.

  • UBS Group reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 64,879 CureVac shares in Q1 2026, an estimated $293K.
  • UBS Group first reported a position in CureVac in Q3 2020 and held it in 22 quarters.
  • UBS Group's CureVac position peaked at $8.35M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.